Tempest Therapeutics, Inc.

The momentum for this stock is not very good. Tempest Therapeutics, Inc. is not a good value stock. Tempest Therapeutics, Inc. has good growth characteristics. Tempest Therapeutics, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Tempest Therapeutics, Inc..
Log in to see more information.
TPST Fundamental Data by TradingView

News

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Globe Newswire BRISBANE, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...\n more…

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Globe Newswire BRISBANE, Calif., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated...\n more…

Tempest Therapeutics appoints Troy Wagner as VP, quality assurance
Tempest Therapeutics appoints Troy Wagner as VP, quality assurance

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance
Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance

Globe Newswire Expansion of leadership team to strengthen global clinical expertiseBRISBANE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology...\n more…

Why Is Small-Cap Tempest Therapeutics Stock Trading Higher On Thursday?
Why Is Small-Cap Tempest Therapeutics Stock Trading Higher On Thursday?

Benzinga Tempest Therapeutics receives FDA feedback on the Phase 3 trial design for amezalpat (TPST-1120) in combination with Tecentriq and Avastin to treat first-line hepatocellular carcinoma. Study to begin in Q1 2025.\n more…

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma
Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

Globe Newswire Broad agreement on pivotal Phase 3 study plan, including use of current amezalpat dose and scheduleOverall survival, the strongest result from the Phase 2 trial, will be the primary study...\n more…